- Clinical Study
- Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer
-
Myung-Chul Lee, Min Joo Kim, Hoon Sung Choi, Sun Wook Cho, Guk Haeng Lee, Young Joo Park, Do Joon Park
-
Endocrinol Metab. 2019;34(2):150-157. Published online May 10, 2019
-
DOI: https://doi.org/10.3803/EnM.2019.34.2.150
-
-
6,702
View
-
137
Download
-
28
Web of Science
-
31
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Thyroid-stimulating hormone (TSH) suppression is recommended for patients who undergo thyroidectomy for differentiated thyroid cancer (DTC). However, the impact of TSH suppression on clinical outcomes in low-risk DTC remains uncertain. Therefore, we investigated the effects of postoperative TSH levels on recurrence in patients with low-risk DTC after thyroid lobectomy. MethodsPatients (n=1,528) who underwent thyroid lobectomy for papillary thyroid carcinoma between 2000 and 2012 were included in this study. According to the mean and dominant TSH values during the entire follow-up period or 5 years, patients were divided into four groups (<0.5, 0.5 to 1.9, 2.0 to 4.4, and ≥4.5 mIU/L). Recurrence-free survival was compared among the groups. ResultsDuring the 5.6 years of follow-up, 21 patients (1.4%) experienced recurrence. Mean TSH levels were within the recommended low-normal range (0.5 to 1.9 mIU/L) during the total follow-up period or 5 years in 38.1% or 36.0% of patients. The mean and dominant TSH values did not affect recurrence-free survival. Adjustment for other risk factors did not alter the results. ConclusionSerum TSH levels did not affect short-term recurrence in patients with low-risk DTC after thyroid lobectomy. TSH suppression should be conducted more selectively.
-
Citations
Citations to this article as recorded by
- Dynamic risk assessment in patients with differentiated thyroid cancer
Erika Abelleira, Fernando Jerkovich Reviews in Endocrine and Metabolic Disorders.2024; 25(1): 79. CrossRef - Stimulating thyroglobulin to TSH ratio predict long-term efficacy of 131I therapy in patients with differentiated thyroid cancer after total thyroidectomy: a retrospective study
Xue Yin, Chao Lu, Danyang Sun, Yanhui Ji, Yan Wang, Hongyuan Zheng, Ziyu Ma, Qiang Jia, Jian Tan, Wei Zheng Endocrine.2024;[Epub] CrossRef - Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study)
Ja Kyung Lee, Eu Jeong Ku, Su-jin Kim, Woochul Kim, Jae Won Cho, Kyong Yeun Jung, Hyeong Won Yu, Yea Eun Kang, Mijin Kim, Hee Kyung Kim, Junsun Ryu, June Young Choi Annals of Surgical Treatment and Research.2024; 106(1): 19. CrossRef - Impact of a mobile health intervention based on multi-theory model of health behavior change on self-management in patients with differentiated thyroid cancer: protocol for a randomized controlled trial
Yang Jiang, Xiangju Sun, Maomin Jiang, Hewei Min, Jing Wang, Xinghua Fu, Jiale Qi, Zhenjie Yu, Xiaomei Zhu, Yibo Wu Frontiers in Public Health.2024;[Epub] CrossRef - Risk of Subsequent Primary Cancers in Thyroid Cancer Survivors according to the Dose of Levothyroxine: A Nationwide Cohort Study
Min-Su Kim, Jang Won Lee, Min Kyung Hyun, Young Shin Song Endocrinology and Metabolism.2024; 39(2): 288. CrossRef - Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer
Arash Abiri, Khodayar Goshtasbi, Sina J. Torabi, Edward C. Kuan, William B. Armstrong, Tjoson Tjoa, Yarah M. Haidar Otolaryngology–Head and Neck Surgery.2023; 168(4): 745. CrossRef - Outcomes of Patients with an Intermediate‐Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma
Kiyomi Horiuchi, Mikiko Fujimoto, Kamio Hidenori, Yusaku Yoshida, Eiichiro Noguchi, Yoko Omi, Takahiro Okamoto World Journal of Surgery.2023; 47(10): 2464. CrossRef - Effects of Isthmus Preservation on Postoperative Hypothyroidism after Lobectomy
Yeong San Jeon, Wan Wook Kim International Journal of Thyroidology.2023; 16(1): 120. CrossRef - Physical activity and reduced risk of fracture in thyroid cancer patients after thyroidectomy — a nationwide cohort study
Jinyoung Kim, Kyungdo Han, Jin-Hyung Jung, Jeonghoon Ha, Chaiho Jeong, Jun-Young Heu, Se-Won Lee, Jeongmin Lee, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Ki-Hyun Baek Frontiers in Endocrinology.2023;[Epub] CrossRef - Association between thyroid stimulating hormone levels and papillary thyroid cancer risk: A meta-analysis
Bin Xu, Shu-Yan Gu, Ning-Ming Zhou, Jun-Jie Jiang Open Life Sciences.2023;[Epub] CrossRef - The Relationship between Thyrotropin Serum Concentrations and Thyroid Carcinoma
Xueqi Zhang, Lijun Tian, Di Teng, Weiping Teng Cancers.2023; 15(20): 5017. CrossRef - Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy
Benjamin J. Gigliotti, Sina Jasim Endocrine.2023; 83(2): 251. CrossRef - Optimal Serum Thyrotropin Level for Patients with Papillary Thyroid Carcinoma After Lobectomy
Siyuan Xu, Ying Huang, Hui Huang, Xiaohang Zhang, Jiaxin Qian, Xiaolei Wang, Zhengang Xu, Shaoyan Liu, Jie Liu Thyroid.2022; 32(2): 138. CrossRef - Optimal Thyrotropin Following Lobectomy for Papillary Thyroid Cancer: Does It Exist?
Lindsay Bischoff, Megan R. Haymart Thyroid.2022; 32(2): 117. CrossRef - Evaluation of ITGA3 as a Biomarker of Progression and Recurrence in Papillary Thyroid Carcinoma
Guoliang Zhang, Bing Li, Yuanmei Lin Frontiers in Oncology.2022;[Epub] CrossRef - The Question of an Optimal TSH Goal After Lobectomy for Papillary Thyroid Cancer
Bernadette Biondi Clinical Thyroidology.2022; 34(2): 67. CrossRef - Is Maintaining Thyroid-Stimulating Hormone Effective in Patients Undergoing Thyroid Lobectomy for Low-Risk Differentiated Thyroid Cancer? A Systematic Review and Meta-Analysis
Ho-Ryun Won, Eonju Jeon, Jae Won Chang, Yea Eun Kang, Kunho Song, Sun Wook Kim, Dong Mee Lim, Tae Kwun Ha, Ki-Wook Chung, Hyo-Jeong Kim, Young Joo Park, Bon Seok Koo Cancers.2022; 14(6): 1470. CrossRef - Research Review of Thermal Ablation in the Treatment of Papillary Thyroid Carcinoma
Di Ou, Chen Chen, Tian Jiang, Dong Xu Frontiers in Oncology.2022;[Epub] CrossRef - CACA guidelines for holistic integrative management of thyroid cancer
Minghua Ge, Ming Gao, Ruochuan Cheng, Xiaohong Chen, Haixia Guan, Yansong Lin, Shaoyan Liu, Yu Wang, Chuanming Zheng, Xiangqian Zheng Holistic Integrative Oncology.2022;[Epub] CrossRef - Value of thyroglobulin post hemithyroidectomy for cancer: a literature review
Saam S. Tourani, Bill Fleming, Justin Gundara ANZ Journal of Surgery.2021; 91(4): 724. CrossRef - Pros and cons of hemi‐thyroidectomy for low‐risk differentiated thyroid cancer
Alexander J. Papachristos, Anthony Glover, Mark S. Sywak, Stan B. Sidhu ANZ Journal of Surgery.2021; 91(9): 1704. CrossRef - Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review
Carla GAMBALE, Rossella ELISEI, Antonio MATRONE Minerva Endocrinologica.2021;[Epub] CrossRef - The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study
Yi Dou, Yingji Chen, Daixing Hu, Xinliang Su Frontiers in Endocrinology.2021;[Epub] CrossRef - Controversy: For or against thyroid lobectomy in > 1 cm differentiated thyroid cancer?
Fabrice Menegaux, Jean-Christophe Lifante Annales d'Endocrinologie.2021; 82(2): 78. CrossRef - Thyroid cancer, recent advances in diagnosis and therapy
Fadi Nabhan, Priya H. Dedhia, Matthew D. Ringel International Journal of Cancer.2021; 149(5): 984. CrossRef - A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol
Eun Kyung Lee, Yea Eun Kang, Young Joo Park, Bon Seok Koo, Ki-Wook Chung, Eu Jeong Ku, Ho-Ryun Won, Won Sang Yoo, Eonju Jeon, Se Hyun Paek, Yong Sang Lee, Dong Mee Lim, Yong Joon Suh, Ha Kyoung Park, Hyo-Jeong Kim, Bo Hyun Kim, Mijin Kim, Sun Wook Kim, Ka Endocrinology and Metabolism.2021; 36(3): 574. CrossRef - Long-term follow-up results of PTMC treated by ultrasound-guided radiofrequency ablation: a retrospective study
Yalin Zhu, Ying Che, Shuhang Gao, Shuangsong Ren, Mengying Tong, Lina Wang, Fang Yang International Journal of Hyperthermia.2021; 38(1): 1225. CrossRef - Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up
Soo Young Kim, Hee Jun Kim, Seok-Mo Kim, Hojin Chang, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park Frontiers in Endocrinology.2020;[Epub] CrossRef - Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
Dana M. Hartl, Joanne Guerlain, Ingrid Breuskin, Julien Hadoux, Eric Baudin, Abir Al Ghuzlan, Marie Terroir-Cassou-Mounat, Livia Lamartina, Sophie Leboulleux Cancers.2020; 12(11): 3282. CrossRef - Annual Neck Ultrasonography Surveillance between 3 to 12 Years after Thyroid Lobectomy for Papillary Thyroid Microcarcinoma
Jin Gu Kang, Jung Eun Choi, Soo Jung Lee, Su Hwan Kang International Journal of Thyroidology.2020; 13(2): 142. CrossRef - Thyroid hormone therapy in differentiated thyroid cancer
Giorgio Grani, Valeria Ramundo, Antonella Verrienti, Marialuisa Sponziello, Cosimo Durante Endocrine.2019; 66(1): 43. CrossRef
- Preoperative Localization and Intraoperative Parathyroid Hormone Assay in Korean Patients with Primary Hyperparathyroidism
-
Eirie Cho, Jung Mi Chang, Seok Young Yoon, Gil Tae Lee, Yun Hyi Ku, Hong Il Kim, Myung-Chul Lee, Guk Haeng Lee, Min Joo Kim
-
Endocrinol Metab. 2014;29(4):464-469. Published online December 29, 2014
-
DOI: https://doi.org/10.3803/EnM.2014.29.4.464
-
-
3,532
View
-
32
Download
-
8
Web of Science
-
4
Crossref
-
Abstract
PDFPubReader
- Background
The intraoperative parathyroid hormone (IOPTH) assay is widely used in patients with primary hyperparathyroidism (PHPT). We investigated the usefulness of the IOPTH assay in Korean patients with PHPT. MethodsWe retrospectively reviewed the data of 33 patients with PHPT who underwent parathyroidectomy. Neck ultrasonography (US) and 99mTc-sestamibi scintigraphy (MIBI scan) were performed preoperatively and IOPTH assays were conducted. ResultsThe sensitivity of neck US and MIBI scans were 91% and 94%, respectively. A 50% decrease in parathyroid hormone (PTH) levels 10 minutes after excision of the parathyroid gland was obtained in 91% (30/33) of patients and operative success was achieved in 97% (32/33) of patients. The IOPTH assay was 91% true-positive, 3% true-negative, 0% false-positive, and 6% false-negative. The overall accuracy of the IOPTH assay was 94%. In five cases with discordant neck US and MIBI scan results, a sufficient decrease in IOPTH levels helped the surgeon confirm the complete excision of the parathyroid gland with no additional neck exploration. ConclusionThe IOPTH assay is an accurate tool for localizing hyperfunctioning parathyroid glands and is helpful for evaluating cases with discordant neck US and MIBI scan results.
-
Citations
Citations to this article as recorded by
- Single-Center Experience of Parathyroidectomy Using Intraoperative Parathyroid Hormone Monitoring
Seong Hoon Kim, Si Yeon Lee, Eun Ah Min, Young Mi Hwang, Yun Suk Choi, Jin Wook Yi Medicina.2022; 58(10): 1464. CrossRef - The natural history and hip geometric changes of primary hyperparathyroidism without parathyroid surgery
Kyong Yeun Jung, A. Ram Hong, Dong Hwa Lee, Jung Hee Kim, Kyoung Min Kim, Chan Soo Shin, Seong Yeon Kim, Sang Wan Kim Journal of Bone and Mineral Metabolism.2017; 35(3): 278. CrossRef - The utility of the radionuclide probe in parathyroidectomy for primary hyperparathyroidism
MS Lim, M Jinih, CH Ngai, NM Foley, HP Redmond The Annals of The Royal College of Surgeons of England.2017; 99(5): 369. CrossRef - Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee Endocrinology and Metabolism.2015; 30(1): 47. CrossRef
- The Clinical Importance of Minimal Extrathyroid Extension on Tumor Recurrence in Patients with Papillary Thyroid Carcinoma.
-
Jung Min Kim, Yun Yong Lee, Chang Woon Choi, Sang Moo Lim, Seung Sook Lee, Soo Youn Cho, Guk Haeng Lee, Byeong Cheol Lee, Ka Hee Yi
-
Endocrinol Metab. 2010;25(4):340-346. Published online December 1, 2010
-
DOI: https://doi.org/10.3803/EnM.2010.25.4.340
-
-
2,209
View
-
24
Download
-
4
Crossref
-
Abstract
PDF
- BACKGROUND
We wanted to evaluate whether a minimal extrathyroid extension (METE) is associated with the clinicopathological parameters that are indicative of a poor prognosis, including lymph node metastasis, distant metastasis at the time of the initial diagnosis and tumor recurrence, in patients with papillary thyroid carcinoma (PTC), and especially in the patients with papillary thyroid microcarcinoma (PTMC). METHODS: We retrospectively evaluated the medical records of patients with PTC and who had undergone total thyroidectomy with/without subsequent 131I remnant ablation at the Korea Cancer Center Hospital from January 1998 through December 2005. A total of 557 patients with PTC were enrolled in the study. We excluded 13 patients with an unknown status of extension and 29 patients with massive ETE. RESULTS: Of the 515 patients, 401 were found to have a METE. We analyzed the 464 patients who were without distant metastasis at the time of the initial diagnosis and who had a follow-up duration of more than 6 months. METE was not significantly associated with tumor recurrence during the follow-up period (median follow-up period: 122 months, range: 6-142 months): 8% vs. 15% of the patients with and without METE had tumor recurrence, respectively (P = 0.069 by the log-rank test). We analyzed the effect of tumor size in the patients with METE. Size was not significantly associated with tumor recurrence (P = 0.374 by the log-rank test). CONCLUSION: These findings suggest that METE might not be a prognostic factor to predict tumor recurrence in patients with PTC, including PTMC.
-
Citations
Citations to this article as recorded by
- Sonographic Assessment of the Extent of Extrathyroidal Extension in Thyroid Cancer
Sae Rom Chung, Jung Hwan Baek, Young Jun Choi, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Jeong Hyun Lee Korean Journal of Radiology.2020; 21(10): 1187. CrossRef - Papillary thyroid microcarcinoma: the significance of high risk features
Nori L. Bradley, Sam M. Wiseman BMC Cancer.2017;[Epub] CrossRef - Clinical and Pathologic Predictors of Lymph Node Metastasis and Recurrence in Papillary Thyroid Microcarcinoma
Saaduddin Siddiqui, Michael G. White, Tatjana Antic, Raymon H. Grogan, Peter Angelos, Edwin L. Kaplan, Nicole A. Cipriani Thyroid.2016; 26(6): 807. CrossRef - High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma
Bo Hyun Kim, Seong-Jang Kim, Keunyoung Kim, Heeyoung Kim, So Jung Kim, Won Jin Kim, Yun Kyung Jeon, Sang Soo Kim, Yong Ki Kim, In Joo Kim Annals of Nuclear Medicine.2015; 29(8): 721. CrossRef
|